Insights - Medicenna (MDNA) put out greater detail on the biomarker data reported last month. The data, albeit early, is showing activity at low doses. With dosing … Continue Reading
Premium: Read NowInsights - Happy 2022 everyone! 2021 was a record year for biotech IPOs. The number of recent crossover rounds suggests that 2022 could be even busier. According … Continue Reading
Premium: Read NowInsights - Medicenna (MDNA) released safety & biomarker data for the first two dose cohorts. Early signs are promising.MDNA’s monotherapy dose escalation will include 6 doses. The first dose … Continue Reading
Premium: Read NowInsights - Affimed hosted their call yesterday to discuss details of AFM13+NK cells from MD Anderson. Overall, the data was very promising as it showed dose response and early durability. AFMD … Continue Reading
Premium: Read NowInsights - “Buy when there’s blood in the streets, even if the blood is your own.” – Nathan Rothschild (banker)“Be greedy when others are fearful.” – Warren … Continue Reading
Premium: Read NowInsights - The latest COVID variant Omicron has been detected in at least 5 US states, with more expected. Worldwide headlines of this variant have caused uncertainty … Continue Reading
Premium: Read NowInsights - Affimed reported surprise data this morning for AFM13+NK cells with partner MD Anderson. This is the data that was expected in mid-December, which now the company will … Continue Reading
Premium: Read Now
